Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
Biogen's Phase 2 CELIA study shows diranersen, an investigational tau-targeting therapy, slowed clinical decline in early Alzheimer's patients by 38% at two years. The 60 mg twice-yearly dose showed the most significant benefits, with a 1.09-point treatment difference on CDR-SB. Data presented at CTAD 2026. Diranersen was well-tolerated with no new safety signals.
How this was made

The 30-second read
Why it matters
The Week 96 results claim increasing treatment effects versus Week 76 and report no new safety signals, which can shift investor expectations for continued development and trial design confidence.
Market read
A conference-stage, longer-horizon efficacy update with quantified endpoint improvements and stated tolerability can drive near-term biotech sentiment and positioning in Alzheimer’s tau therapeutics.
What to watch
The article does not provide Phase 3 timing, regulatory pathway details, or magnitude of biomarker-to-clinical translation beyond tau PET/CSF/plasma signals, leaving key commercialization and efficacy durability questions unanswered.
Background
Diranersen (BIIB080) is an investigational antisense oligonucleotide targeting MAPT mRNA to reduce tau production; CELIA is a Phase 2 randomized, double-blind, placebo-controlled dose-ranging study with an ongoing open-label extension.
Ticker impact
Biogen announced new two-year Phase 2 CELIA data for diranersen, showing increasing clinical benefit at Week 96 with no new safety signals.
Likely upward bias as investors price in improved Phase 2 durability and reduced perceived clinical risk, pending Phase 3 confirmation.
The article provides specific Week 96 efficacy deltas across multiple endpoints and states tolerability with no new safety signals, which can move biotech sentiment and expectations for next-stage trials.
Market effects
Reinforces tau-targeting ASO narrative in early Alzheimer’s, potentially lifting sentiment across Alzheimer’s biotech and tau-modulating platforms.
Primarily US biotech sentiment via Nasdaq-listed Biogen; limited direct regional spillover beyond healthcare/biopharma investors.
Conference-stage efficacy updates can influence global clinical-decision expectations and partner/investor sentiment for tau therapeutics.
Counterpoint
Open-label extension-derived comparisons and placebo-equivalent design may overstate durability versus a fully randomized two-year control, so enthusiasm could fade if Phase 3 design or endpoints disappoint.
Key entities
- companyBiogen Inc.
Sponsor of diranersen and publisher of the Phase 2 CELIA two-year Week 96 efficacy and safety update.
- drugDiranersen (BIIB080)
Investigational tau-targeting antisense oligonucleotide therapy in early Alzheimer’s disease.
- clinical_trialCELIA study
Phase 2 randomized, placebo-controlled dose-ranging study with an open-label extension used for the two-year analyses.
- conferenceCTAD 2026
Conference where the two-year data were presented.


